Identifying which type of patient would benefit from a particular crystalloid is essential in intravenous (IV) fluid therapy, according to a presentation at the 4th SG-ANZICS Intensive Care Forum 2017 held in Singapore.
Bed strain in intensive care unit (ICU) can significantly affect patient outcomes, in particular mortality, but increasing the number of beds available does not help solve the issues faced in a strained ICU, according to a presentation at the recent SG- SG-ANZICS Intensive Care Forum (SG-ANZICS 2017) in Singapore.
The use of noninvasive ventilation (NIV) in patients admitted to the general ward for acute exacerbation of chronic obstructive pulmonary disease (COPD) appears to be safe and cost-effective, according to a study presented at the 4th SG-ANZICS Intensive Care Forum (SG-ANZICS 2017) held in Singapore.
Early and adequate feeding of critically ill patients requiring ICU admission improves survival and reduces infective complications, says a nutrition specialist at the 4th SG – ANZICS Intensive Care Forum 2017 held in Singapore.
The ongoing APROCCHSS* and ADRENAL** trials may help elucidate the indication of corticosteroid therapy in preventing mortality in septic shock, according to a presentation at the recent SG-ANZICS Intensive Care Forum (SG-ANZICS 2017) held in Singapore.
Patients who had intra-aortic balloon pump (IABP) for 4 days or had IABP insertion during coronary angiography and/or percutaneous coronary intervention (PCI) had an increased risk of developing vascular complications, suggests a study presented at the 4th SG-ANZICS* Intensive Care Forum (SG-ANZICS 2017) held recently in Singapore.
Ventilator hyperinflation (VHI) may be safely used in critical trauma patients with pulmonary complications, as the intervention results in no adverse changes in cardiovascular (CV) parameters, according to a study presented at the 4th SG-ANZICS Intensive Care Forum 2017 in Singapore.
The assessment of diaphragm thickening fraction (DTF) may help predict simple weaning and identify patients who are ready to wean prior to a T-piece trial, according to a study presented at the 4th SG-ANZICS Intensive Care Forum 2017 held in Singapore.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.